Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score
暂无分享,去创建一个
R. Greil | K. Harrington | I. Braña | A. Psyrri | D. Rischin | R. Swaby | B. Burtness | N. Ngamphaiboon | B. Hughes | R. Mesía | A. Bratland | D. Soulières | G. de Castro | T. Fuereder | M. Tahara | P. Neupane | T. Rordorf | W. Z. Wan Ishak | N. Basté | B. Gumuscu | G. de Castro Jr | J. Ge | Gilberto de Castro Jr
[1] J. Lunceford,et al. Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma , 2022, Journal for ImmunoTherapy of Cancer.
[2] K. Harrington,et al. Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer , 2020, Modern Pathology.
[3] Hung-Ming Wang,et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study , 2019, The Lancet.
[4] O. V. Matorin,et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study , 2019, The Lancet.
[5] K. Li,et al. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis. , 2018, Oral oncology.
[6] M. Preusser,et al. PD‐1 and PD‐L1 expression in HNSCC primary cancer and related lymph node metastasis – impact on clinical outcome , 2018, Histopathology.
[7] Jonathan C. Cheng,et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012 , 2018, British Journal of Cancer.
[8] A. Iyer,et al. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome , 2017, Front. Pharmacol..
[9] P. Stephens,et al. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers , 2017, Molecular Cancer Therapeutics.
[10] J. Radford. Nivolumab for recurrent squamous-cell carcinoma of the head and neck , 2016, BDJ.
[11] N. Rizvi,et al. PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction? , 2016, Journal of Immunotherapy for Cancer.
[12] J. Lunceford,et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. , 2016, The Lancet. Oncology.
[13] Razelle Kurzrock,et al. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy , 2015, Molecular Cancer Therapeutics.
[14] G. Freeman,et al. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection , 2007, Nature Immunology.